Tempus AI's growth and partnerships make it an attractive investment. See why TEM stock is a solid Buy due to its ...

Piper Sandler analyst David Westenberg raised the firm’s price target on Tempus AI (TEM) to $70 from $40 and keeps a Neutral rating on ...

Stifel has downgraded Tempus AI (NASDAQ:TEM) to hold from buy, citing valuation and uncertainty about core growth in 2025.

Stifel Nicolaus analyst Daniel Arias downgraded the rating on Tempus AI, Inc. Class A (TEM – Research Report) to a Hold yesterday, ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.

Fintel reports that on November 11, 2024, Stifel downgraded their outlook for Tempus AI (NasdaqGS:TEM) from Buy to Hold. ...

With Ambry Genetics in tow, Eric Lefkofsky's biotech startup hopes to accelerate its drive toward turning a profit.

CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing ...

In addition, please check the fund’s top five holdings to know its best picks in 2024. Baron Discovery Fund highlighted ...

On Friday, Tempus AI Inc (TEM) stock saw a modest uptick, ending the day at $73.77 which represents a slight increase of $16.98 or 29.90% from the prior close of $56.79. The stock opened at $56.79 and ...

Northwestern Medicine will be the first system to use Tempus' new algorithm to identify patients at risk for developing ...

Tempus AI said it agreed to pay $375 million in cash and $225 million in shares to acquire genetic testing company Ambry Genetics. Ambry conducts hereditary cancer screening and currently serves as ...